经贵要静脉入路新型血管内热消融技术治疗盆腔静脉疾病的前瞻性描述性研究
本研究为前瞻性单中心描述性队列研究,纳入10例保守治疗无效的慢性盆腔痛女性患者,经右贵要静脉入路使用1470nm激光对反流的性腺静脉行血管内热消融。技术成功率100%,3个月CT证实全部完全闭塞,无并发症,疼痛快速持续缓解,支持该技术的可行性与早期安全性。
要点
- 经贵要静脉入路1470nm EVLA治疗性腺静脉反流技术上可行,本组技术成功率达100%。
- 本组无术中及术后并发症,均为日间手术,疼痛评分快速下降并维持至6个月。
- 需更大样本多中心随机试验及12个月以上随访验证远期疗效与成本效益。
核心结论
- 经贵要静脉入路1470nm血管内热消融治疗反流性腺静脉可行、安全,早期技术和临床成功率高,可日间出院且本组无并发症。
研究设计与样本
- 前瞻性单中心描述性队列研究,2025年1月至6月纳入10例18-50岁慢性盆腔痛保守治疗无效且多普勒证实盆腔静脉曲张的女性患者。
主要发现
- 基线症状为盆腔痛100%、痛经77%、性交痛94%、性交后疼痛97%,平均VAS 7.8/10.0。
- 平均靶静脉直径14mm(范围10-17mm),全部为左侧性腺静脉反流(S2V2,非血栓性)。
- 手术时间45-60分钟,估计失血量约10mL,无术中或术后并发症。
- 技术成功率100%,3个月CT示10/10完全闭塞,多普勒超声示盆腔静脉曲张消退。
- VAS在24小时降至1-2/10,6个月为0.4/10,30天内无阿片类药物使用、再入院或再干预。
关键数值与推荐
- 纳入标准:慢性盆腔痛保守治疗无效,多普勒证实盆腔静脉曲张(静脉直径>6mm、低流速波形或Valsalva诱发反流)。
- 消融参数:400μm、1470nm径向光纤,功率6-8W,控制回撤,靶向性腺静脉近段/中段。
- 随访方案:48小时门诊、4周经阴道多普勒超声、3个月静脉期CT、6个月临床评估。
临床怎么用
- 对于保守治疗无效、多普勒证实性腺静脉反流的盆腔静脉疾病女性,可考虑经贵要静脉入路行1470nm EVLA作为无植入物的治疗选择。
- 术前怀疑压迫综合征时行CT静脉造影,术中透视识别输尿管以保障安全。
- 该技术在本组实现日间手术并快速缓解疼痛,但需在更大样本中验证后方可推广。
局限性
- 单中心、小样本(10例)描述性研究,缺乏对照组。
- 随访时间短(6个月),未报告12个月以上结局。
- 需多中心随机试验、盲法影像审阅、标准化患者报告结局及成本效益分析进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pelvic venous disorders causing pelvic congestion syndrome are a common, underdiagnosed source of chronic pelvic pain. Standard coil/sclerosant embolization may be limited by migration, incomplete occlusion, postembolization syndrome, symptom recurrence, and cost. Endovenous thermal ablation (EVLA) could provide precise, device-free closure with faster recovery and lower cost. OBJECTIVE: We evaluated the feasibility, safety, and early efficacy of basilic access 1470-nm EVLA for refluxing gonadal veins in women with pelvic venous disorders. METHODS: Prospective, single-center descriptive cohort study (January to June 2025). Ten women (aged 18-50 years) with chronic pelvic pain refractory to conservative therapy and Doppler-confirmed pelvic varices (venous diameter >6 mm, low-flow waveforms, or Valsalva-induced reflux) underwent EVLA. When compressive syndrome was suspected, preprocedural computed tomography (CT) venography was obtained. Procedures used local anesthesia with conscious sedation via right basilic access. A 400-μm, 1470-nm radial fiber delivered 6 to 8 W with controlled pullback targeting proximal/mid gonadal vein segments. Diagnostic venography of the left renal, left common iliac, and internal iliac veins ruled out compression and mapped reflux/varices; the ureter was identified fluoroscopically for safety. Primary end points were technical success (cessation of reflux/closure on completion venography and 3-month CT) and safety (periprocedural complications). Secondary end points include same-day discharge, pain (visual analog scale [VAS]), and imaging resolution of pelvic varices. The follow-up protocol consisted of a 48-hour clinic visit, 4-week transvaginal Doppler ultrasound examination, 3-month venous-phase CT, and 6-month clinical assessment. RESULTS: The mean patient age was 37 years (range, 28-45 years). Baseline symptoms were pelvic pain in 100%, dysmenorrhea in 77%, dyspareunia in 94%, and postcoital pain in 97%; the mean VAS 7.8 out of 10.0. All cases were day-case (hospital stay 0 days). The mean target vein diameter was 14 mm (range, 10-17 mm). All patients had left gonadal vein reflux (Symptoms-Varices-Pathophysiology S2V2; nonthrombotic). The procedure time was 45 to 60 minutes and estimated blood loss was approximately 10 mL. No intraoperative or postoperative complications occurred (no perforation, bleeding, ureteral injury, thrombosis, access issues, or contrast reactions). Technical success was 100%; 3-month CT scans confirmed complete occlusion in 10 of the 10 patients, and Doppler ultrasound examination showed resolution of pelvic varices. Pain improved rapidly (VAS 1-2 out of 10 at 24 hours) and was sustained (0.4 out of 10 at 6 months); there were no opioid use, readmissions, or reinterventions at 30 days. Patient-reported quality of life improved across follow-up. CONCLUSIONS: Basilic access 1470-nm EVLA of refluxing gonadal veins is feasible, safe, and shows high early technical and clinical success with same-day discharge and no complications in this pilot cohort. Larger multicenter randomized trials with follow-up beyond 12 months, blinded imaging review, standardized patient-reported outcomes, and cost-effectiveness analyses are warranted.
引用
- Moreno L, Rivero F, Forero Ramirez N, et al. A novel endovascular thermal ablation technique for pelvic venous disorders via basilic vein access: A prospective descriptive study. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 41519470. doi:10.1016/j.jvsv.2026.102442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。